|
Mechanism of Tissue Regeneration
This invention is a biodegradable patch seeded with human neonatal dermal fibroblasts and human induced pluripotent stem cell derived cardiomyocytes which helps regenerate endogenous cardiomyocytes in adult murine, rat, and swine models of myocardial infarction as a cause of chronic heart failure (CHF). This invention details changes in specific gene...
Published: 5/24/2023
|
Inventor(s): Steven Goldman, Jennifer Koevary, Jordan Lancaster, Jordan Fink, Adrian Grijalva
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Regenerative Medicine / Tissue Engineering, Technology Classifications > Life Sciences > Therapeutics
|
|
Druggable Formulation for Mu/Delta Opioid Antagonist for Enhancing Pain Therapy and Treatment of Opioid Withdrawal
This invention provides compositions and method of pain treatment using a mu/delta opioid receptor heterodimer (MDOR) antagonist which has improved druggability by nanoformulation and/or glycosylation to increase their bioavailability and efficacy. These modified antagonists and formulations provide for enhancement of opioid agonist therapy's antinociceptive...
Published: 5/23/2023
|
Inventor(s): John Streicher, Robin Polt, Lajos Szabo, Wafaa Alabsi, Parthasaradhi Reddy Tanguturi
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Neurology
|
|
A Recombinant Protein to Restore the Anti-Cancer Activity of Immune Cells
This invention is a recombinant protein that is designed to restore the activity of immune cells that have been exhausted in patients with cancer. This invention focuses specifically on the restoration of the anti-cancer activity of immune cells, in particular natural killer (NK) cells.
Background:
Immune cell-based therapies are a widely utilized...
Published: 4/13/2023
|
Inventor(s): Youngwook Won, Seungmin Han, David Bull
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Oncology
|
|
Method and System for Passive and Active Agent Delivery for Biomarker and Treatment Means
Plant-based extracellular vesicles have features leading to low immunogenicity with innate bioactive agents for targeting and/or treating specific biological effects. They can also be used as carriers with cargo drug from natural or synthetic products with higher bioavailability. The variety of plant categories also provide broad resources for lower...
Published: 4/6/2023
|
Inventor(s): Frederic Zenhausern, Jerome Lacombe, Ashlee Harris, Zhu Zhao
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Biomarkers, Technology Classifications > Life Sciences > Drug Delivery
|
|
Allosteric Inhibitors of the Main Protease of SARS-CoV-2
In this report, the SARS-CoV-2 3CLpro was expressed and purified. By using a FRET-based enzymatic assay, the researchers have screened a library consisting of more than 300 different niclosamide derivatives and identified three molecules JMX0286, JMX0301, and JMX0941 as potent allosteric inhibitors against SARS-CoV-2 3CLpro, with IC50 values like that...
Published: 4/5/2023
|
Inventor(s): Hongmin Li, Subodh Samrat, Zhong Li, Jia Zhou, Jimin Xu
Keywords(s):
Category(s): Technology Classifications, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios, Technology Classifications > Healthcare Portfolios > Infectious Diseases
|
|
Calcimycin as Antifungals
A new antifungal treatment is necessary, as pathogens evolve and develop immunity to current methods. Here, the inventors present calcimycin (CMN) as a novel treatment of cryptococcosis caused by Cryptococcus neoformans (Cne) and likely Cryptococcus gattii (Cga). CMN prevents the protein from continuing to splice. While the current treatment methods...
Published: 4/3/2023
|
Inventor(s): Hongmin Li, Zhong Li, Qing-yu Zhang
Keywords(s):
Category(s): Technology Classifications, Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios, Technology Classifications > Healthcare Portfolios > Infectious Diseases
|
|
Glycopeptide-Lipid Supramolecular Assembly
This invention provides an approach, including compositions and methods for delivering glycolipids to biological cells. This is done using supramolecular assemblies made of glycopeptides and amphipathic molecules, which may be used to deliver therapeutics, including glycosylated hormones or their analogues, such as endomorphin, dermorphin, angiotensin,...
Published: 4/13/2023
|
Inventor(s): Robin Polt, Michael Heien
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Drug Delivery, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Healthcare Portfolios > Neurology
|
|
Targeted Cancerous Cell Specific Suicide Gene Therapy
This invention describes a novel cancer therapy method that induces cell death mechanisms in only cancer cells.
Background:
The current standard of care for cancer therapy in many cases is chemotherapy. Chemotherapy, like many cancer treatments, causes significant amounts of healthy cells to die in addition to the cancer cells, leading to the well-known...
Published: 4/3/2023
|
Inventor(s): Ravi Goyal
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Oncology
|
|
An Efficient And Improved Chemical Conversion Of The Natural Product Physachenolide D (LG-01) To Its Analogue LG-134 With Potent Anticancer Activity
Invention: An improved process of chemical conversion of the natural plant product physachenolide D (PCD) to a C-18 analogue (LG-134) of physachenolide C (PCC).Background: The standard yield of LG-134 using current methods is relatively low at 1/3 resultant from original products. This method allows for the yield to be double current chemical processes....
Published: 4/3/2023
|
Inventor(s): Leslie Gunatilaka, Kithsiri Wijeratne, Yaming Xu
Keywords(s):
Category(s): Technology Classifications > Agriculture & Horticulture, Technology Classifications > Life Sciences > Therapeutics
|
|
DYRK/CLK PROTACS
This invention describes a set of novel molecules that target and degrade DYRK/CLK for several potential therapeutic purposes.
Background:
Proteolysis-targeting chimeric molecules (PROTACs) are small molecules used to decrease a gene’s protein expression by targeting the protein for ubiquitination and degradation after it is created. This mechanism...
Published: 4/3/2023
|
Inventor(s): Christopher Hulme, Kevin Schofield, Walter Becker, Garrit Wilms
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
